What the Evidence Actually Says About Wound Healing
When it comes to treating a cut or abrasion, most of us reach for whatever’s in the medicine cabinet, usually Neosporin or a generic triple-antibiotic ointment. But a centuries-old alternative, the Chinese/Japanese herbal ointment Shiunko (Ziyun Gao), has a surprisingly different evidence profile, and the difference reveals something important about how “wound care” actually works.
The Case for Shiunko
Shiunko’s key active ingredient is shikonin, derived from the root of Lithospermum erythrorhizon. In animal studies, it consistently outperforms saline controls and matches gentamicin and silver sulfadiazine for both infection control and reepithelialization on sterile and contaminated wounds. Fibroblast studies show it upregulates TGF-β and boosts collagen secretion, a real mechanistic signal.
Human data is thinner but meaningful: a phase II RCT in 40 patients with cutaneous leishmaniasis found Shiunko produced significantly faster lesion healing than placebo (69% vs. 22% reduction by week 16). It’s a narrow population, but it’s real randomized human evidence, something most OTC wound products can’t claim.
The Case Against Neosporin
Neosporin’s evidence is larger in volume but far less consistent. One 426-patient military hospital trial found triple-antibiotic ointment beat plain petrolatum on infection rates. But a larger 933-patient dermatologic surgery trial found no significant difference between petrolatum and bacitracin. The often-cited 1996 JAMA study reached the same conclusion: no meaningful infection-rate advantage over petrolatum, but a clear increase in allergic reactions in the antibiotic group.
That allergy risk isn’t trivial: neomycin causes allergic contact dermatitis in roughly 11% of patch-tested individuals, bacitracin in about 8%, and ACD can itself slow healing. A 2018 meta-analysis summed it up well – topical antibiotics beat placebo, but only marginally, and antiseptics are a reasonable resistance-conscious alternative.
The Real Difference: Passive vs. Active Healing
Here’s the deeper point. Neosporin, bacitracin, and petrolatum are all fundamentally passive. They block infection or moisture loss, but they don’t accelerate the biology of repair. Shiunko is doing something different: shikonin appears to actively drive angiogenesis and granulation tissue formation, not just suppress bacteria.
That puts it in the same functional category as prescription-grade regenerative treatments, most notably becaplermin (Regranex, the one FDA-approved topical growth factor drug.) In a 922-patient RCT, becaplermin increased complete healing of diabetic ulcers by 43% and cut healing time by 32%, by directly recruiting fibroblasts and endothelial cells. It’s restricted to chronic, non-healing wounds (and carries a cancer-risk warning with heavy use), but it proves the concept: actively promoting angiogenesis, rather than just preventing infection, meaningfully changes healing outcomes.
The Takeaway
Neosporin, doesn’t clearly beat plain Vaseline on infection rates while adding real allergy risk. Shiunko is an accessible topical actively pushing the biology of repair forward, with mechanistic and preliminary clinical evidence to back it up. It isn’t a large evidence base by pharmaceutical standards, but it’s arguably better-aimed at what wound healing actually needs.
